Boosting mRNA Potential for Therapeutics, Gene-Editing & Vaccine Applications With Scalable Design, Guided Delivery, & Validated Clinical Safety for Patients
With proof-of-concept after the COVID-19 pandemic, the mRNA space stands on firmer ground and is now making headlines that prove its value across new diseases. From MHRA’s latest guidance on mRNA personalized cancer vaccines to the world’s first RNA-based CRISPR therapy for Baby KJ, doors are opening to revolutionary therapeutics and gene editing applications.
The 5th mRNA-Based Therapeutics Summit Europe is the ultimate biopharma platform diving into novel mRNA, sa-RNA and circular RNA design to delivery innovations, giving you the latest insights and connections to turn these breakthroughs into action. Enhanced with the brand-new Gene Editing Focus Day to harness mRNA's power through transient editing strategies, and Investor-Led sessions on what makes an mRNA platform fundable in 2026, leave this meeting with tried and tested strategies to de-risk your programs and secure partnerships in today’s competitive landscape.
Join 170+ senior leaders from Moderna, AstraZeneca, CybernaX Bio, Avocet Bio, and others working on R&D, CMC, business development, and regulatory affairs for three days of learning, networking, and collaboration to put you at the forefront of mRNA and gene editing innovation in 2026.
 |
Recent mRNA News |
European Investment Bank and the European Commission provide up to €95 million to BioNTech for its mRNA vaccine manufacturing facility in Kigali signalling Europe’s commitment to modular, scalable mRNA-manufacturing infrastructure
|
Recent mRNA News |
A landmark analysis titled “Europe’s RNA Immunotherapy Enters a New Phase” reports that the continent is now seeing first-in-region in vivo trials, national/regional pipeline infrastructure, and manufacturing consolidation all pointing to mRNA’s transition from promise to practice in Europe
|
Recent mRNA News |
The European Directorate for the Quality of Medicines & HealthCare (EDQM) and the European Pharmacopoeia Commission adopted three general texts for mRNA vaccines (Ph. Eur. 5.36, 5.39 & 5.40) covering LNP-formulated mRNA, active mRNA substances and DNA templates marking a significant step toward harmonised European standards for mRNA quality control
|
Recent mRNA News |
The European Medicines Agency’s draft guideline on the quality aspects of mRNA vaccines includes expanded scope for self-amplifying RNA and alternative delivery systems, reflecting how regulatory thinking in Europe is evolving to accommodate next-generation mRNA therapeutics
|
Recent mRNA News |
CREATE Medicines’s pivot to multi-lineage RNA programming and the broader trend of RNA-immunotherapy deal-making in Europe signal that the continent is building the industrial and regulatory scaffolding necessary to drive deeper mRNA innovation beyond the vaccines era
Explore the Full Event Guide
- Reshape gene editing strategies with mRNA and explore its role in safer, transient editing, and novel delivery approaches
- Win the race for the next big mRNA breakthrough with end-to-end insights to take you from early discovery to late-stage manufacturing
- Discover how to best secure funding for your company in 2026 with firsthand insights from experienced investors in mRNA drug pipeline expansion
Industry Speakers
Investors Speaking
Divide & Conquer: End-to-End Insights for Your Entire Team
Pre-Clinical & Clinical Development Track
Follow the journey from early discovery to first-in-human trials, uncovering how smarter pre-clinical models and clinical strategies are accelerating safe, effective mRNA therapies to patients.
Top Sessions Cover:
Technology Innovation & Manufacturing Track
Explore the breakthroughs in mRNA design, delivery systems, and scalable manufacturing that are transforming innovation into reliable, clinic-ready products.
Top Sessions Cover:
Investor-Led Exclusive Sessions
From billion-euro megadeals to targeted niche investments, Europe’s mRNA landscape is surging. Learn directly from investors on how to best capitalise on the available funding opportunities in 2026
Top Sessions Cover:
Official Partners
Data from later clinical development stage/clinical data was presented. This was interesting.
Senior Vice President, BioNTech
This was an excellent conference, by far one of the best mRNA conferences I have attended. Excellent meeting to meet the leaders in the field. The scientific program, the exchange and the networking were excellent.
Chief Executive Officer, DivinCell
The diversity of topics and attendees was good (suppliers, drug developers, CDMOs, regulatory specialists)
Director, Merck KGaA
Attending Companies Include
Explore the Agenda
Dive into cutting-edge mRNA-based therapeutics with insights from leading biopharma, biotech, and academic experts.
Partner With Us
Showcase your technologies and services to senior decision-makers driving next-generation mRNA innovation.
Join Biopharma Experts
Be part of the only European meeting uniting pre-clinical, clinical, manufacturing, regulatory, and investor experts in the mRNA space.